PIK3CA and ESR1 mutations detected in circulating tumor DNA (ctDNA) are predictive factors for late-line hormone-based therapies in ER+/HER2-metastatic breast cancer (MBC)

被引：0
|
作者：
Chen, Tom Wei-Wu [1 ]
Dai, Ming-Shen [2 ]
Chang, Dwang-Ying [1 ]
Lin, Ching-Hung [3 ]
Chen, I-Chun [3 ]
Wang, Ming-Yang [1 ]
Huang, Ling-Yi [4 ]
Hsu, An [4 ]
Zhuo, De-Wei [4 ]
Tan, Kien Thiam [4 ]
Lu, Yen-Jung [4 ]
Chang, Shu-Han [1 ]
Cheng, Ann-Lii [3 ]
Lu, Yen-Shen [1 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Triserv Gen Hosp, Taipei, Taiwan
[3] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[4] ACT Genom Co Ltd, Taipei, Taiwan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P5-01-21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-01-21
引用
收藏
页数：3
相关论文
共 46 条
  • [41] Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (June, 10.1007/s10549-024-07427-2, 2024)
    Bhave, Manali A.
    Quintanilha, Julia C. F.
    Tukachinsky, Hanna
    Li, Gerald
    Scott, Takara
    Ross, Jeffrey S.
    Pasquina, Lincoln
    Huang, Richard S. P.
    McArthur, Heather
    Levy, Mia A.
    Graf, Ryon P.
    Kalinsky, Kevin
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (03) : 611 - 614
  • [42] Orthogonal assessment of PIK3CA and ESR1 mutation detection in longitudinal cfDNA samples from endocrine-resistant HR+/HER2-advanced breast cancer patients using dPCR and NGS-based SafeSEQ technology
    Antras, Jesus Fuentes
    Garcia-Barberan, Vanesa
    Moreno, Fernando
    Sloane, Hillary
    Lopez-Cade, Igor
    De Luna, Alicia
    Pascual, Alejandro
    Ramirez-Ruda, Carmen
    Lorca, Victor
    Flores, Paloma
    Perez-Segura, Pedro
    Ocana, Alberto
    Preston, Jennifer
    Quinn, Hannah
    Jones, Frederick
    Garcia-Saenz, Jose Angel
    CANCER RESEARCH, 2022, 82 (04)
  • [43] PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.
    Bidard, Francois Clement
    Sabatier, Renaud
    Berger, Frederique
    Pistilli, Barbara
    Dalenc, Florence
    Rouge, Thibault De La Motte
    Frenel, Jean-Sebastien
    Dubot, Coraline
    Ladoire, Sylvain
    Ferrero, Jean-Marc
    Stefani, Laetitia
    Lortholary, Alain
    Hardy-Bessard, Anne-Claire
    Grenier, Julien
    Everhard, Sibille
    Jeannot, Emmanuelle
    Proudhon, Charlotte
    Lemonnier, Jerome
    Delaloge, Suzette
    Bachelot, Thomas Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2-advanced breast cancer (BC): First results from the randomized, phase Ill BELLE-2 trial
    Baselga, J.
    Im, S-A
    Iwata, H.
    Clemons, M.
    Ito, Y.
    Awada, A.
    Chia, S.
    Jagiello-Gruszfeld, A.
    Pistilli, B.
    Tseng, L-M
    Hurvitz, S.
    Masuda, N.
    Cortes, J.
    De Laurentiis, M.
    Arteaga, C. L.
    Jiang, Z.
    Jonat, W.
    Hachemi, S.
    Le Mouhaer, S.
    Di Tomaso, E.
    Urban, P.
    Massacesi, C.
    Campone, M.
    CANCER RESEARCH, 2016, 76
  • [45] POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.
    Baird, Richard D.
    Van Rossum, Annelot
    Oliveira, Mafalda
    Beelen, Karin
    Garcia-Corbacho, Javier
    Mandjes, Ingrid A. M.
    Vallier, Anne-Laure
    van Werkhoven, Erik D.
    Kumar, Sanjeev Srinivas
    van Tinteren, Harm
    Beddowes, Emma
    Rosing, Hilde
    Schrier, Mariette
    Schultink, Aurelia de Vries
    Saura, Cristina
    Bernards, Rene
    Tabernero, Josep
    Cortes, Javier
    Caldas, Carlos
    Linn, Sabine C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
    Turner, Nick
    Rugo, Hope S.
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Prat, Aleix
    Bachelot, Thomas
    Chia, Stephen
    Balbin, Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
12345